Profil
Richard Johnson is associated with the firm Upperton Ltd.
since 1999, where he holds the position of Chief Strategy Officer & Director.
He is the founder of Upperton Ltd.
which was founded in 1999.
Postes actifs de Richard Johnson
| Sociétés | Poste | Début |
|---|---|---|
Upperton Ltd.
 Upperton Ltd. Miscellaneous Commercial ServicesCommercial Services Upperton Ltd. is a British pharmaceutical company that offers a range of services to support product development, including identification, development, monitoring, and quality control testing. Upperton is based in Nottingham, UK, and was founded in 1999 by Richard Johnson. The company has an experienced analytical team that works in conjunction with formulators to ensure the success of all projects. The company offers flexible and dynamic GMP manufacturing services for clinical supplies, from first in human through to phase III clinical supplies manufacturing. The company has extensive experience taking research projects from early proof of concept and feasibility through scale-up and onto clinical manufacture for a range of common dosage forms. The CEO is Nikki Whitfield. | Fondateur | 01/08/1999 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Upperton Ltd.
Upperton Ltd. Miscellaneous Commercial ServicesCommercial Services Upperton Ltd. is a British pharmaceutical company that offers a range of services to support product development, including identification, development, monitoring, and quality control testing. Upperton is based in Nottingham, UK, and was founded in 1999 by Richard Johnson. The company has an experienced analytical team that works in conjunction with formulators to ensure the success of all projects. The company offers flexible and dynamic GMP manufacturing services for clinical supplies, from first in human through to phase III clinical supplies manufacturing. The company has extensive experience taking research projects from early proof of concept and feasibility through scale-up and onto clinical manufacture for a range of common dosage forms. The CEO is Nikki Whitfield. | Commercial Services |
